Cautious Hold Rating for Geron’s Imetelstat Amid Incremental Clinical Trial Updates
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Emily Bodnar maintains a Hold rating on Geron’s stock due to incremental clinical trial updates on imetelstat. The data shows a correlation between cytopenias and clinical response in LR-MDS patients, suggesting treatment efficacy. However, improvements in survival rates are modest, leading to a cautious outlook. TR | OpenAI also reiterates a Hold rating with a $1.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments